Fradafiban is a non-peptidic platelet glycoprotein IIb/IIIa complex antagonist that potently inhibits human platelet aggregation in vitro by reversibly and selectively binding to the human platelet GPIIb/IIIa complex with high affinity (Kd = 148 nM); it exhibits very limited oral activity in vivo, likely due to its high polarity and poor gastrointestinal absorption.